Van citroenwater tot injecties voor gewichtsverlies: wie wil afvallen ziet online door de bomen het bos niet meer. Ozempic wordt gepresenteerd als hét nieuwe wondermiddel, maar is dat terecht? Of zitten er meer haken en ogen aan dan TikTok je doet geloven? In deze aflevering duiken Tom en Alexander diep in de hype rondom Ozempic en andere afslankmedicatie. Wat doet het middel precies in je lichaam? Voor wie is het bedoeld, en wat gebeurt er als je ermee stopt? Met wetenschap als leidraad scheiden ze feiten van fabels. In deze aflevering: 💉 Wat is Ozempic precies en hoe werkt het in je lichaam?⏳ Verkort Ozempic je levensduur, of juist niet?😬 Bestaat “Ozempic face” echt, of is dat gewoon normaal bij afvallen?🔁 Kom je na Ozempic altijd weer aan?🍋 Helpt citroenwater, zout en wandelen écht om snel af te vallen? Tom stelt de vragen, Alexander ontrafelt de claims. Zodat jij aan het eind weet: wat is een bewezen hulpmiddel, wat is overschat, en wanneer een simpele leefstijlverandering minstens zo effectief is als een spuitje. Lang zal je leven, maar wel met verstand. 🎧 Geproduceerd door Tonny Media👉 Volg ons op Instagram, TikTok en YouTube🥼Alle onderzoeken die in deze aflevering worden besproken vind je hier: Aamir AB, Latif R, Alqoofi JF, Almarzoq FA, Fallatah JO, Hassan GA, Saab FAAAA. Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data. J Clin Med Res. 2025 May;17(5):285-296. doi: 10.14740/jocmr6231. Epub 2025 May 13. PMID: 40503067; PMCID: PMC12151102. McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, Goossens GH, Monami M, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025 Oct;31(10):3317-3329. doi: 10.1038/s41591-025-03978-z. Epub 2025 Oct 2. PMID: 41039116; PMCID: PMC12532627. Bacha Z, Javed J, Sheraz M, Sikandar M, Zakir M, Ali MA, Khan M, Iqbal A, Rehman A, Alam U, Ahmed R. Efficacy and Safety of Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cardiol Rev. 2025 Sep 19. doi: 10.1097/CRD.0000000000001057. Epub ahead of print. PMID: 40968407. Sillassen CDB, Petersen JJ, Faltermeier P, Yucel D, Siddiqui F, Andersen RK, Graever L, Bjerg JL, Kamp CB, Grand J, Dominguez H, Frølich A, Gæde P, Gluud C, Mathiesen O, Jakobsen JC. The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis. BMC Med. 2025 Nov 24;23(1):654. doi: 10.1186/s12916-025-04486-0. PMID: 41286875; PMCID: PMC12642075. Yao Y, Liu N, Chen S, Sun M, Guo Y. Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease. Eur J Med Res. 2025 Nov 4;30(1):1059. doi: 10.1186/s40001-025-03241-8. PMID: 41188987; PMCID: PMC12584374. Wu R, Xing B, Zhou Z, Yu L, Wang H. Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Eur J Med Res. 2025 Sep 2;30(1):835. doi: 10.1186/s40001-025-03124-y. PMID: 40890879; PMCID: PMC12403603. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131. Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025 Nov 18;86(20):1805-1819. doi: 10.1016/j.jacc.2025.08.027. Epub 2025 Aug 27. PMID: 40892610. Shuja SH, Shuja MH, Shaukat A, Hannat R, Ahmed I, Adam S, Abdelkhalek A, Changez MIK, Ullah I, Ahmed R, Cortese B. GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis. Am J Cardiol. 2026 Jan 1;258:268-275. doi: 10.1016/j.amjcard.2025.09.039. Epub 2025 Sep 27. PMID: 41022246. Anyiam O, Ardavani A, Rashid RSA, Panesar A, Idris I. How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis. Obes Rev. 2025 Jul;26(7):e13916. doi: 10.1111/obr.13916. Epub 2025 Apr 3. PMID: 40181228; PMCID: PMC12137041. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024 Nov;12(11):785-787. doi: 10.1016/S2213-8587(24)00272-9. Epub 2024 Sep 9. PMID: 39265590. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025 Mar;164:156113. doi: 10.1016/j.metabol.2024.156113. Epub 2024 Dec 22. PMID: 39719170. Kolli RT, Aoutla S, Jyothi N, Mohamed Kalifa MRH, Raju A, Cheenikkal Muralidharan K. Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs. Cureus. 2025 Oct 19;17(10):e94926. doi: 10.7759/cureus.94926. PMID: 41116804; PMCID: PMC12535773. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025 Aug;26(8):e13929. doi: 10.1111/obr.13929. Epub 2025 Apr 4. PMID: 40186344. Quarenghi M, Capelli S, Galligani G, Giana A, Preatoni G, Turri Quarenghi R. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. J Clin Med. 2025 May 28;14(11):3791. doi: 10.3390/jcm14113791. PMID: 40507553; PMCID: PMC12155999. Kılıç S. Facial aging after GLP-1 receptor agonist-induced weight loss: the emerging Ozempic face phenomenon. J Diabetes Metab Disord. 2025 Nov 6;24(2):261. doi: 10.1007/s40200-025-01778-3. PMID: 41210112; PMCID: PMC12592601. Chu J, Zhang H, Wu Y, Huang Y, Zhu T, Zhou Z, Wang H. Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine. 2025 Aug 30;88:103464. doi: 10.1016/j.eclinm.2025.103464. PMID: 40926900; PMCID: PMC12414836. Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, Eng PC, Tan BYQ, Sattar N, Dalakoti M, Sia CH. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care. 2025 Feb 1;48(2):292-300. doi: 10.2337/dc24-1678. PMID: 39841962. Codella R, Senesi P, Luzi L. GLP-1 agonists and exercise: the future of lifestyle prioritization. Front Clin Diabetes Healthc. 2025 Nov 24;6:1720794. doi: 10.3389/fcdhc.2025.1720794. PMID: 41367404; PMCID: PMC12683586. De Amicis R, Foppiani A, Leone A, Sileo F, Menichetti F, Mambrini SP, Pellizzari M, Tucci M, Martini D, Del Bo C, Riso P, Bertoli S, Battezzati A. How sustainable are hypocaloric and balanced diets for weight loss? Nutr Metab (Lond). 2025 Jun 10;22(1):58. doi: 10.1186/s12986-025-00937-w. PMID: 40495206; PMCID: PMC12153144. Cigrovski Berkovic M, Ruzic L, Cigrovski V, Strollo F. Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs. World J Diabetes. 2025 Sep 15;16(9):109123. doi: 10.4239/wjd.v16.i9.109123. PMID: 40980310; PMCID: PMC12444289. Ruseva A, Michalak W, Fabricatore A, Hartaigh BÓ, Zhao Z, Wang J, Umashanker D. Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months). Curr Med Res Opin. 2025 Dec 6:1-12. doi: 10.1080/03007995.2025.2591464. Epub ahead of print. PMID: 41351543. Reiss AB, Gulkarov S, Lau R, Klek SP, Srivastava A, Renna HA, De Leon J. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025 Mar 13;15(3):408. doi: 10.3390/biom15030408. PMID: 40149944; PMCID: PMC11940170. See omnystudio.com/listener for privacy information.
